Eurofins Technologies is launching a new range of serology-based antibody detection kits used to identify patients exposed to COVID-19.

Eurofins said the first enzyme-linked immunosorbent assay (ELISA) tests are expected to receive CE mark certification by April 16, and it will also seek an Emergency Use Authorization from the FDA.

The company said it is ramping up capabilities at six production sites in the U.S., Europe, Japan and India in response to a spike in demand around the world.